Elias Zerhouni will take control of Sanofi-Aventis' research and development starting Jan. 1 as part of a restructuring to improve the company's pipeline of drugs and vaccines. Sanofi said this move will boost opportunities and adeptness for the R&D division, as the company works to have vaccines make up for sales lost to generic competition. Zerhouni will replace Marc Cluzel, who will remain as a consultant for R&D.

Full Story:

Related Summaries